Latest Conference Articles

A large proportion of nAMD patients treated with anti-VEGF therapies continue to have active disease and fluid.

Top websites for macular degeneration content do not necessarily have better quality information or readability.

In data presented virtually during the ASRS 2020 meeting, investigators find X-82 is non inferior in visual acuity outcomes.

The addition of oral zeaxanthin reduces the risk of subfoveal choroidal neovascularization development compared to previously published studies.

A look at how the specialty functions in telemedicine, and how it could work better with primary care physicians and endocrinologists.

How the condition affects both the vision and mindset of patients, and what clinical outcomes for anti-VEGF research do to address it.

New phase 1/2 data shows AAV-RGPR may benefit a previously untreated population of inherited retina disease boys and young men.

A look at how primary care patients begin to present with diabetic retinopathy risk.

New PANORAMA findings could give ophthalmologists confidence in longer time between administrations after year 2.

New research shows patients with both conditions have greater levels of particular cytokines and metabolic proteins.

Where do investigators go next with the 8000-plus COPD patient research?

Both dosage groups of the study drug achieved at least a 50-meter increase from baseline to week 24 on the six-minute walk distance test.

Treatment with treprostinil of up to 12 breaths per session four-times per data was well-tolerated, with a safety profile consistent with previous studies.

In an era of triple therapy combinations, what might a tailored approach look like?

New findings from the 8000-plus patient ETHOS trial shows triple inhaler therapy siginificantly betters patient mortality and symptoms over 52 weeks versus dual therapy.

After promising early findings for the investigative therapy in a rare form of blindness, investigators turn to the next phase.

New research from ARVO 2020 suggests patients with diabetic eye disease can still experiences losses in visual acuity, even with glycemic control.

A survey of 19 patients with hereditary retinitis pigmentosa details the impact of the disease on the quality of life and daily activity of patients and caregivers.

Women with recent gestational diabetes who use the intervention see less retention of weight than those who do not use the intervention.

An analysis of data from 5 PIONEER trials is shedding new light on the impact of oral semaglutide based on background glucose-lowering therapy.

The drug also reduced the risk of myocardial infarction and stroke.

Taking testosterone while enrolled in a lifestyle program reduces glucose levels and risk of type 2 diabetes.

Discussing how advances in care and therapeutic agents have impacted the management of diabetes in 2020.

Gauging patient wellbeing prior to intravitreal injections may help inform clinicians as to who may fare worse with the treatment.

Todd Hobbs, MD, breaks down research presented at ADA 2020.

Dr. Richard Furie explains the link between systemic lupus erthematosus and COVID-19.

Discussing an analysis of retrospective claims data to examine the incidence of herpes zoster in patients with T2DM and how it impacts their diabetes.

Lead investigator of VERTIS-CV discusses results of the phase 3 trial examining ertugliflozin's impact on cardiovascular health.

A breakdown of a new 12-month, phase 1b/2 assessment of the RNA therapy in patients with LCA10.

The prevention of type 2 diabetes is possible and has important clinical benefits.